Sarabia Vallejo, ÁlvaroLópez-Alvarado Gutiérrez, María PilarMenéndez Ramos, José Carlos2024-12-042024-12-042023-07-05Álvaro Sarabia-Vallejo, Pilar López-Alvarado, J. Carlos Menéndez, Small-molecule theranostics in Alzheimer's disease, European Journal of Medicinal Chemistry, Volume 255, 2023, 115382, https://doi.org/10.1016/j.ejmech.2023.115382.0223-523410.1016/j.ejmech.2023.115382https://hdl.handle.net/20.500.14352/1120622023 Acuerdos transformativos CRUEAlzheimer's Disease (AD) remains one of the most challenging health-related issues for our society. It is becoming increasingly prevalent, especially in developed countries, due to the rising life expectancy and, moreover, represents a considerable economic burden worldwide. All efforts at the discovery of new diagnostic and therapeutic tools in the last decades have invariably met with failure, making AD an incurable illness and underscoring the need for new approaches. In recent years, theranostic agents have emerged as an interesting strategy. They are molecules able to simultaneously provide diagnostic information and deliver therapeutic activity, allowing for the assessment of the molecule activity, the organism response and the pharmacokinetics. This makes these compounds promising for streamlining research on AD drugs and for their application in personalized medicine. We review here the field of small-molecule theranostic agents as promising tools for the development of novel diagnostic and therapeutic resources against AD, highlighting the positive and significant impact that theranostics can be expected to have in the near future in clinical practice.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal articlehttps://doi.org/10.1016/j.ejmech.2023.115382open access615:54615.31Alzheimer's diseaseTheranostic agentsβ-amyloid proteinPET imagingOptical imagingFluorescent probesQuímica farmaceútica2390 Química Farmacéutica